Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study).
Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study).
复制标题
曲妥珠单抗新辅助化疗后病理完全缓解和无病生存的预测因素：针对 HER2 阳性原发性乳腺癌患者的多中心回顾性观察研究（JBCRG-C03 研究）。
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Toi M.
中科院分区：
文献类型：
--
作者：
Takada M;Ishiguro H;Nagai S;Ohtani S;Kawabata H;Yanagita Y;Hozumi Y;Shimizu C;Takao S;Sato N;Kosaka Y;Sagara Y;Iwata H;Ohno S;Kuroi K;Masuda N;Yamashiro H;Sugimoto M;Kondo M;Naito Y;Sasano H;Inamoto T;Morita S;Toi M.
